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Abstract
A considerable body of evidence supports the role of mitochondrial dysfunction in psychiat-
ric disorders and mitochondrial DNA (mtDNA) mutations are known to alter brain energy
metabolism, neurotransmission, and cause neurodegenerative disorders. Genetic studies
focusing on common nuclear genome variants associated with these disorders have pro-
duced genome wide significant results but those studies have not directly studied mtDNA
variants. The purpose of this study is to investigate, using next generation sequencing, the
involvement of mtDNA variation in bipolar disorder, schizophrenia, major depressive disor-
der, and methamphetamine use. MtDNA extracted from multiple brain regions and blood
were sequenced (121 mtDNA samples with an average of 8,800x coverage) and compared
to an electronic database containing 26,850 mtDNA genomes. We confirmed novel and
rare variants, and confirmed next generation sequencing error hotspots by traditional se-
quencing and genotyping methods. We observed a significant increase of non-synonymous
mutations found in individuals with schizophrenia. Novel and rare non-synonymous muta-
tions were found in psychiatric cases in mtDNA genes: ND6, ATP6, CYTB, and ND2. We
also observed mtDNA heteroplasmy in brain at a locus previously associated with schizo-
phrenia (T16519C). Large differences in heteroplasmy levels across brain regions within
subjects suggest that somatic mutations accumulate differentially in brain regions. Finally,
multiplasmy, a heteroplasmic measure of repeat length, was observed in brain from selec-
tive cases at a higher frequency than controls. These results offer support for increased
rates of mtDNA substitutions in schizophrenia shown in our prior results. The variable levels
of heteroplasmic/multiplasmic somatic mutations that occur in brain may be indicators of ge-
netic instability in mtDNA.
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Introduction
The mitochondrial hypothesis of psychiatric disorders derives from evidence of energy metab-
olism alterations, high prevalence of affective disorders in patients with mitochondrial disor-
ders, and from increased maternal heritability [1]. Cross-sectional risk studies have revealed a
significantly higher risk for schizophrenia in relatives who shared mitochondrial DNA
(mtDNA) with a schizophrenia patient [2]. However, studies concentrating on major mtDNA
haplogroups have failed to reveal clear differences between these major haplogroups in terms
of risk to develop psychiatric disorders [3–7]. Recent studies have also suggested that variants
in mtDNA can contribute to the risk to develop major depressive disorder (MDD), bipolar dis-
order (BD) and schizophrenia (SZ) [8–13]. Additionally, some patients with mitochondrial dis-
orders caused by known mtDNA mutations often present psychiatric symptoms [14–16],
suggesting a major role of mtDNA mutations in the predisposition to psychiatric disorders. In-
cidentally, in a large population analysis, common mtDNA variants have been shown to also
increase the risk of many seemingly unrelated diseases, some affecting the brain such as ischae-
mic stroke, multiple sclerosis and Parkinson’s disease [13].
The mitochondrial DNA (mtDNA) is a 16.6 kb circular molecule maternally transmitted
and located inside the mitochondrion. The main role of mitochondria is to produce energy
through oxidative phosphorylation (OXPHOS). The mtDNA genome encodes 13 OXPHOS
proteins, 22 tRNAs, and 12S and 16S rRNA genes. Because each cell contains between 100 to
1000 mitochondria, and each mitochondrion contains a variable number of mtDNA molecules
[17, 18], mtDNAmutations can be homoplasmic (present in all copies of the mtDNA genome)
or heteroplasmic, with mutations only present in a fraction of the mtDNAmolecules. In the
past, cloning and Sanger sequencing have been used to investigate heteroplasmy levels, but re-
cent next-generation sequencing (NGS) advancements now allow the study of mtDNA varia-
tion with sufficient coverage to uncover heteroplasmy [9, 19, 20].
Genetic predisposition for psychiatric disorders has been extensively studied but few candi-
date gene variants have been validated across cohorts. However, most of these studies have fo-
cused on nuclear genes instead of mtDNA variants. The mitochondrial genome is particularly
sensitive to oxidative stress and tends to accumulate somatic mutations with age, particularly
in high energy demanding regions such as the brain. Chronic methamphetamine (METH) use
is also associated with increased oxidative stress and mitochondrial dysfunction [21]. We
therefore included a group of METH users to investigate the chronic effects of this drug on so-
matic mutations in METH susceptible regions of the brain.
Prior studies, using NGS, have shown an increase in somatic homoplasmic and heteroplas-
mic mtDNAmutations in cancer [22], cardiomyopathy [23], and aging [24, 25]. We recently
used NGS to investigate the involvement of mtDNA somatic homoplasmic mutations in a
small sample of brains from patients with psychiatric disorders [9].
In this study, we investigated the involvement of homoplasmic, multiplasmic and hetero-
plasmic variation in mtDNA from 69 subjects, using NGS on 11 brain regions and blood sam-
ples from patients with psychiatric conditions and normal controls. Our working hypothesis
was that a greater number of mtDNA mutations would occur in cases compared to controls.
We also hypothesized that somatic mutations can appear in some brain regions and accumu-
late to a deleterious level and play a role in the pathophysiology of psychiatric disorders. Brain
tissue is a unique resource to investigate the occurrence of heteroplasmic mutations not neces-
sarily present in peripheral tissues such as blood.
MtDNAMutations in Psychiatric Disorders
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Results
We analyzed 121 complete mtDNA sequences from 69 subjects, including samples from sever-
al brain regions and from blood for three subjects (S1 and S2 Tables). All 121 mtDNA se-
quences passed stringent quality control and were deposited at NCBI (http://www.ncbi.nlm.
nih.gov/) accession numbers KC257284-KC257404. Despite differences in overall coverage, re-
flecting differences between the two platforms efficiency and our multiplexing, we did not ob-
serve major differences in the variants reported by the two Illumina platforms (GAII (cohort 1)
and HiSeq (cohort 2)). GAII produced an average coverage for the variants of 3,766
(min = 100, max = 15,620) and the HiSeq platform an average of 9,775 (min = 1,114,
max = 107,710), with a combined overall average coverage of 8,850.
Mitochondrial DNA variation
Of the 3,670 mtDNA variants across the 121 samples, the majority were homoplasmic (3177)
and 493 were heteroplasmic. The majority of heteroplasmic variants were C>T or A>G transi-
tions, consistent with the expected transition to transversion rate [26].
Consensus mtDNA sequences of the 121 samples were used to build a phylogenetic tree (S1
Fig) following established PhyloTree topology and haplogroup nomenclature24. Subjects were
distributed across diverse haplogroups with no clear clustering of diagnosis, suggesting that
there is no specific increase in the predisposition to psychiatric disorders in mitochondria hap-
logroups (S1 Fig). Given the perfect agreement of consensus sequences across brain regions
and blood, we decided to focus on the DLPFC data to compare subjects based on diagnosis. We
observed a total of 1748 sequence variants in the DLPFC from 63 unique subjects, but many of
them were haplogroup specific and reflected divergence from the mitochondrial revised Cam-
bridge Reference Sequence (rCRS; GenBank accession number NC_012920)[27]/. The rCRS,
often used as the reference, is a useful tool to compare mitochondrial genomes but does not
represent the most common haplotype or an ancestral haplotype, it is simply one haplotype.
One subject with schizophrenia, for instance, was identical to the rCRS, while a normal control
of African American ancestry carried a large number of divergent loci compared to the rCRS.
We therefore excluded the major haplogroup defining variants to explore the specific involve-
ment of mitochondrial variation in psychiatric disorders. A total of 1,175 variants in the
DLPFC were further investigated, 984 were homoplasmic (S3 Table) and mainly located in the
hypervariable region of the mtDNA, and 191 were heteroplasmic (see section regarding hetero-
plasmic variation).
Homoplasmic variants
Of the 984 homoplasmic variants, 141 were located within genes and were non-synonymous,
therefore potentially functional (S4 Table). Comparison of variants only observed in cases or
only observed in controls revealed 49 non-synonymous variants (37 loci) only observed among
43 cases (Table 1) versus 12 non-synonymous variants only present in the 20 controls. Of
these 37 loci, a total of 8 were predicted using Polyphen as being possibly/probably damaging
mutations. There were 80 shared variants between cases and controls. The ratio of the number
of non-synonymous mutations to genomes sequenced revealed a significantly higher
(p = 0.024) number of mutations in SZ (1.57) versus controls (0.55) (Table 2). We next tested
whether the distribution of the total number of non-synonymous mutations in cases was differ-
ent compared to controls and found a non-significant trend for five or more non-synonymous
mutations in cases compared to controls (p = 0.068, S5 Table). We found six homoplasmic
non-synonymous mutations that have not been previously reported in MITOMAP, mtDB, or
PhyloTree (Table 3). Two of these mutations were only found in an online ancestry database
MtDNAMutations in Psychiatric Disorders
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Table 1. Non-synonymous homoplasmic substitutions at 37 loci were found only present in cases but not in control DLPFC samples.





3509* ND1 1 1 T C Ile68Thr benign H61 3 P03886
3796 ND1 1 1 2 A G Thr164Ala benign H1b1, H1b1 157 P03886
3992 ND1 2 2 C T Thr229Met benign H4a1a1a, H2a2a1 212 P03886
4024 ND1 2 2 A G Thr240Ala benign H4a1a1a, H2a2a1 166 P03886
4025 ND1 1 1 C T Thr240Met benign H3h 254 P03886
4561 ND2 1 1 T C Val31Ala benign K2a10 221 P03891
4732 ND2 1 1 A G Asn88Ser benign U5b2a1a1b 198 P03891
4824 ND2 1 1 2 A G Thr119Ala possibly
damaging
A2d, A2p 746 P03891
4924* ND2 1 1 G C Ser152Thr benign U5a1d2b 7 P03891
5073# ND2 1 1 A G Ile202Val benign K1b2b 1 P03891
5277 ND2 1 1 T C Phe270Leu benign A2p 75 P03891
5913 COX1 1 1 G A Asp4Asn benign K1b2b 191 P00395
6366 COX1 1 1 G A Val155Ile benign A2d 98 P00395
6480 COX1 1 1 G A Val193Ile benign I2d 70 P00395
8108 COX2 1 1 A G Ile175Val benign A2d 45 P00403
8463* ATP8 1 1 A G Tyr33Cys probably
damaging
X2c1b 8 P03928
8519 ATP8 1 1 G A Glu52Lys possibly
damaging
I4a 63 P03928
8794 ATP6 1 1 2 C T His90Tyr benign A2d, A2p 726 P00846
8843 ATP6 1 1 T C Ile106Thr possibly
damaging
T2b4 119 P00846
9055 ATP6 2 1 3 G A Ala177Thr possibly
damaging
K2a10, K1b2b, K1a3a 1401 P00846
9160# ATP6 1 1 T C Tyr212His probably
damaging
A2d 1 P00846
9210 COX3 1 1 A G Thr2Ala benign H1ag 33 P00414
11016 ND4 1 1 G A Ser86Asn benign H48 184 P03905
11204 ND4 1 1 T C Phe149Leu benign H1 100 P03905
12346 ND5 1 1 C T His4Tyr unknown U2e1c 168 P03915
12397 ND5 1 1 A G Thr21Ala unknown X2a2 134 P03915
12811 ND5 1 1 T C Tyr159His benign H3h 214 P03915
13117 ND5 1 1 A G Ile261Val possibly
damaging
K1a3a 47 P03915
13637 ND5 1 1 A G Gln434Arg benign U5b2a1a1b 243 P03915
13708 ND5 1 1 2 G A Ala458Thr benign J1c2o, U5b2a1a1b 1912 P03915
14110 ND5 1 1 T C Phe592Leu benign H1 247 P03915
14280# ND6 1 1 A C Ser132Ala benign U2e1c 2 P03923
14502 ND6 1 1 T C Ile58Val benign X2a2 111 P03923
14582 ND6 2 2 A G Val31Ala benign H4a1a1a, H2a2a1 164 P03923
14798 CYTB 1 2 1 4 T C Phe18Leu benign J1c2o, K2a10, K1b2b,
K1a3a
2114 P00156
14982# CYTB 1 1 T C Ile79Thr possibly
damaging
V16 2 P00156
15431 CYTB 1 1 G A Ala229Thr benign I3b 326 P00156
The observed haplogroups are randomly distributed. The effect of the amino acid substitutions was determined using Polyphen, damaging mutations are
shown in bold.
* Frequency corresponds to less than 0.1% of 26,850 human mtDNA sequences with size greater than 15.4 kbp collected from GenBank on 25 June
2014.
# Mutations were found in Mitomap (accessed June 2014) as a result of our NCBI data deposit.
doi:10.1371/journal.pone.0127280.t001
MtDNAMutations in Psychiatric Disorders
PLOS ONE | DOI:10.1371/journal.pone.0127280 May 26, 2015 4 / 17
(http://www.ianlogan.co.uk/mtdna.htm) but were not present in the PhyloTree database con-
taining 16,810 mtDNA sequences as of September 2012 [28]. Of these six non-synonymous
novel and rare variants, four were located in ND6, ATP6, CYTB and ND2, and were only ob-
served in cases while several mutations located in ATP6 (Tyr212His, Asn39Thr and
Met140Thr) but present both in controls and cases, which were predicted to be damaging by
Polyphen.
Recently, whole genome sequencing studies have shown increased mutation rates in schizo-
phrenia but only examined nuclear genes [29, 30]. In the current study, we have focused on the
occurrence of nonsynonymous variants in mtDNA as another distinct possible genetic predis-
position to schizophrenia.
Several mutations in ribosomal RNA (rRNA) were also observed only in cases not in con-
trols (S6 Table in gray). The 16S rRNA had 10 variants only observed in cases and the 12S
rRNA had 6 variants that were only observed in cases. The z-score difference between the num-
ber of unique rRNA variants for controls and schizophrenia was not significant (p = 0.15).
Two of these rRNA variants were rare mutations present only in an MDD subject (C1601T)
and in a BD subject (T1861C). After querying multiple online databases these mutations were
found via Ian Logan’s website in accessions HM238202 (Philippines; haplogroup B4a1a) and
JN872374 (Italy; haplogroup U1a3). The C1601T mutation occurs at the 3’ terminus of the 12S
mtDNA rRNA and does not appear to pose functional effects, while the T1861C mutation oc-
curs at a non-complementary bridge, that increases complementarities in that region.
Table 2. The number of non-synonymousmutations shown in S4 Table, was extracted when present only in controls and not cases with psychiat-
ric disorders, and is shown in the row for control subjects.
Subjects Mutations Mutations/subject z-score
Controls 20 11 0.55 -0.990
BD 14 14 1.00 -0.056
MDD 15 13 0.87 -0.333
SZ 14 22 1.57 1.380
The number of non-synonymous mutations found only in cases (and not controls) is shown on each row for each disorder. The ratio of the number of
mutations / subject was calculated for each group, and a z-score for the difference of the observed for each group compared to the entire mean was
calculated. There was a signiﬁcant increase in non-synonymous mutations (p = 0.024, two tailed z-score test) in persons with SZ compared to controls.
doi:10.1371/journal.pone.0127280.t002
Table 3. Novel-rare NSmutations observed in 65 DLPFC brain samples and confirmed by Sanger sequencing, the D-loopmutation is non-coding.
Gene Mutation Coverage Amino Acid Change Age Gender Axis I Haplogroup Status
ATP6 T8945C*1 2820 Met140Thr-damaging 55 M C H1 Rare
ATP6 A8642C 2572 Asn39Thr-damaging 54 M C I1 Novel
ATP6 T9160C 28247 Tyr212His-damaging 50 M BD A2d Novel
CYTB T14982C* 12465 Ile79Thr-moderate 41 F MDD V16 Rare
ND6 A14280C 1113 Ser132Ala-benign 36 M SZ U2e1c Novel
ND2 A5073G 20128 Ile202Val-benign 40 F SZ K1b2b Novel
D-loop T16178G 22475 - 35 M SZ A2p Novel
The effect of the amino acid substitutions was determined using Polyphen.
*Once in submitted online mtDNA sequencing data.
1 T8945C was previously reported by our group [9].
doi:10.1371/journal.pone.0127280.t003
MtDNAMutations in Psychiatric Disorders
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Heteroplasmic variation in mtDNA
We observed a total of 114 heteroplasmic variants in 69 unique mtDNA genomes. Heteroplas-
mic mutations were defined as any variant for which the major allele was<95% of the total of
the observed alleles and a minimum coverage of 200 reads. As expected, the heteroplasmic var-
iants were mainly clustered within the hypervariable region (S7 Table). No clear over-repre-
sentation of heteroplasmic mutations was observed in cases versus controls (except for the
multiplasmy described below). Four heteroplasmic variants with high heteroplasmy and two
multiplasmic variants were successfully validated by Sanger sequencing, confirming the reli-
ability of next generation sequencing and of our quality control criteria for the investigation of
heteroplasmic mtDNA variation (Table 4).
Table 4. Heteroplasmy andmultiplasmy in mtDNA.
Subject Haplogroup Region Diagnosis Gender Age Position Reference Alleles Heteroplasmy Gene Status
Heteroplasmy C-58 L1c3b2 All* C F 58 11696# G G/A 24.8–28.3% ND4 Known
C-58 L1c3b2 All* C F 58 16086 T T/C 67.4–93.7% D-loop Known
M-18 N1a1a1a2 DLPFC MDD M 35 16086 T T/C 85.5% D-loop Known
M-18 N1a1a1a2 DLPFC MDD M 35 16261 C C/T 70.9% D-loop Known
S-111 H56 DLPFC SZ M 47 16519 T T/C 18.9% D-loop Novel
D-84 H69 DLPFC Meth F 34 16519 T T/C 90.0% D-loop Novel
Multiplasmy C-25 H5d All* C M 64 514 (CA)5 (CA)4,5 D-loop Known
C-58 L1c3b2 All* C F 58 514 (CA)5 (CA)4,5 D-loop Known
C-83 U5b1e1 DLPFC C M 44 514 (CA)5 (CA)4,5 D-loop Known
B-71 X2a2 DLPFC BD F 70 514 (CA)5 (CA)4,5 D-loop Known
B-76 I3b DLPFC BD M 39 514 (CA)5 (CA)5,6,7 D-loop Known
B-78 A2d DLPFC BD M 50 514 (CA)5 (CA)4,5 D-loop Known
B-79 H1 DLPFC BD M 43 514 (CA)5 (CA)4,5 D-loop Known
D-85 A2c SN Meth M 35 514 (CA)5 (CA)4,5 D-loop Known
D-86 H2a2b1a SN Meth F 39 514 (CA)5 (CA)5,6 D-loop Known
M-96 I4a DLPFC MDD M 61 514 (CA)5 (CA)4,5 D-loop Known
M-97 H1b1 DLPFC MDD F 63 514 (CA)5 (CA)4,5 D-loop Known
M-98 HV DLPFC MDD F 41 514 (CA)5 (CA)4,5 D-loop Known
S-110 U5b2a1a1b DLPFC SZ F 41 514 (CA)5 (CA)5,6 D-loop Known
S-106 H4a1a1a DLPFC SZ M 59 514 (CA)5 (CA)4,5 D-loop Known
S-107 H2a2a1 DLPFC SZ M 45 514 (CA)5 (CA)4,5 D-loop Known
S-112 A2p DLPFC SZ M 35 514 (CA)5 (CA)4,5 D-loop Known
S-114 K1b2b DLPFC SZ F 40 514 (CA)5 (CA)5,6,7 D-loop Known
C-83E U5b1e1 DLPFC C M 44 D16189 (C)10 (C)9,10,11 D-loop Known
C-90E B2g DLPFC C F 32 D16189 (C)10 (C)9,10,11 D-loop Known
C-89E H1ap1 DLPFC C M 68 D16189 (C)10 (C)9,10,11 D-loop Known
B-77E H1b DLPFC BD M 50 D16189 (C)10 (C)9,10,11 D-loop Known
B-71E X2a2 DLPFC BD F 70 D16189 (C)10 (C)9,10,11 D-loop Known
M-97E H1b1 DLPFC MDD F 63 D16189 (C)10 (C)9,10,11 D-loop Known
The heteroplasmy was calculated from NGS reads and conﬁrmed by Sanger sequencing (Fig 1B). Multiplasmic length polymorphisms were observed in
the D-loop region and showed a trend for over-representation of cases at the 514 (CA)n and the D16189 loci. Multiplasmy was observed about 1.5
times more frequently in cases. Note the tri-allelic multiplasmy results for two subjects (B-76 and S-114) showing 5, 6, and 7 repeat lengths shown in
bold. Heteroplasmy/multiplasmy at all these six loci were also conﬁrmed by Sanger sequencing.
*multiplasmy occurred in all brain regions sequenced.
#Val313Ile.
doi:10.1371/journal.pone.0127280.t004
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We further studied the heteroplasmy of T16519C because of the prior association of this
SNP in a GAIN/WTCCC2 association analysis in SZ and BD [9]. We confirmed a heteroplas-
mic T>C substitution at position 16519 of the mitochondrial genome by allele specific PCR
using locked nucleic acid primers (LNA-primers) as well as by direct sequencing. Low levels of
T16519C heteroplasmy calculated using NGS (~10%) were confirmed by Sanger sequencing as
shown in Fig 1A. Heteroplasmy levels ranged from 1.74%, 18.9%, and 90% calculated from
Illumina NGS results. Interestingly, within the same METH subject, we observed, by NGS and
Sanger, homoplasmy in one brain region (100% C in the SN (sample D-84J) and heteroplasmy
in the DLPFC (sample D-84E) with 90% C and 10% T (Fig 1A). Another example of variable
levels of heteroplasmy was observed across all brain regions for a control subject at mt16086
(Fig 2). Levels ranged from 6.3% in the NACC to 32.5% in the THAL (Fig 2). These findings
clearly demonstrate how heteroplasmic mutations can vary between brain regions of the same
individual. Interestingly, sample D-84 was a METH user but overall we did not observe an in-
crease in somatic mutations associated with METH.
Multiplasmy
Multiplasmy is a heteroplasmic variant occurring at a variable length repeat locus. As an exam-
ple, a repeat of ‘CA’ might be a variable length of 5, 6, and 7 repeats. Thus, a single mtDNA
molecule could have one of these three repeat lengths, and taken together in one individual,
this locus could have all three repeat lengths. Heteroplasmic deletion/insertion polymorphisms
analysis showed a high number of multiplasmic subjects in loci previously known to be particu-
larly hypervariable. Two of these were the poly-cytosine tracts of the hypervariable region, the
D310 poly-C tract (CCCCCTCCCCC from position 303 to 316) and the D16189 poly-C tract
Fig 1. Electropherograms confirming heteroplasmy. A) Heteroplasmy at the 16519 locus confirmed by
Sanger sequencing and showing clear reversals of allele calls and heteroplasmy concordant with NGS
calculated results. The electropherograms for D-84 are from the same subject but from two different brain
regions, D-84E corresponds to DLPFC with 10% T reads and D-84J corresponds to substantia nigra SN with
0% T reads.B)Multiplasmy confirmed by Sanger sequencing. Electropherogram showing a psychiatric
subject with 5, 6 and 7 (CA)n dinucleotide repeats at position 514 in the mtDNA displacement Loop. The
actual number of repeats was determined from the individual reads from the sequencing data, 5 and 6
repeats are over-imposed in the electropherogram, consistent with the NGS results.
doi:10.1371/journal.pone.0127280.g001
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(CCCCCTCCCC from 16184 to 16193)[29, 30]. Multiplasmy was also observed at a locus
known to be a highly variable dinucleotide repeat (CA)n beginning at position 514 of the D-
loop. CA5 is the rCRS sequence and we observed 4, 5, 6, and 7 CA repeats (Fig 1B, Table 4).
Multiplasmy was observed about 1.5 times more frequently in cases (Table 4). Some subjects
(B-76 and S-114) even show tri-allelic multiplasmy with a combination of 5, 6, and 7 CA re-
peats. The ratio of 514 CA deletions across brain regions was variable (S2 Fig), and deletions,
when present, were found across all 10 brain regions.
Blood-brain comparisons
Homoplasmic and heteroplasmic mtDNA variants were compared between blood and 11 brain
regions using samples from three control subjects. Although this is too small of a sample to
draw any definitive conclusion, there was perfect concordance between the homoplasmic vari-
ants found in the 11 brain regions and blood for these three subjects (data not shown), suggest-
ing that blood might be a useful surrogate for the study of homoplasmic mtDNA variation of
germ line origin. However, we observed 5 loci with subtle differences for heteroplasmic variants
that were present at various levels in brain tissue but undetectable in blood using the 5% cutoff
used in the present study (S8 Table). Three of these loci (2487, 5755, and 13706) were not pres-
ent in our database search for reported variants.
Discussion
We observed several novel and rare mtDNA coding homoplasmic mutations in key genes
(ND6, ATP6, CYTB, and ND2). Four novel non-synonymous homoplasmic mutations were
Fig 2. Heteroplasmy levels at position 16086 across 11 brain regions for the same subject.
doi:10.1371/journal.pone.0127280.g002
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validated in different coding regions, three of which were present only in cases and not in con-
trols. There was an excess of non-synonymous homoplasmic mutations found in schizophre-
nia, but not controls. We also confirmed heteroplasmy at a locus in the D-loop region
(T16519C), that we previously reported as being associated with SZ [9]. Excess multiplasmy in
cases at the 16189 poly-C tract and at the 514 (CA)n repeat region was also observed, as well as
single SZ and BD cases showing striking tri-allelic multiplasmy in brain.
Evidence of genomic instability in the form of somatic variation at heteroplasmic and multi-
plasmic loci, and novel and rare variants, are particularly interesting in light of recent studies
using NGS that showed an excess of novel and rare functional variants in the nuclear genome
in different populations [31] and their potential role in complex traits and drug response [32].
A recent study explored the presence of somatic mutations in the aging human brain and
showed an accumulation of deletions and single nucleotide variants with age specially in the
non-coding hyper-variable region [33], consistent with our findings of somatic heteroplasmic
mutations in the adult human brain. The rare and novel coding variants that we found, and the
additional non-synonymous mutations in the mtDNA of psychiatric cases, could also support
abnormal energy metabolism seen using Magnetic Resonance Spectroscopy (MRS). In general,
studies of patients with BD, MDD, and SZ have shown altered energy metabolism in brain [34,
35]. Potential treatment responders to antidepressants sometimes show alterations in MRS
profile of energy metabolites [36]. In an animal model of depression there was an altered meta-
bolic profile that was restored to control levels following antidepressant treatment [37]. In view
of these evidences, it would be interesting to test the effect of mtDNA variation on energy me-
tabolism in peripheral samples from psychiatric patients.
MtDNA can be methylated [38] suggesting an additional control of mitochondrial tran-
scription and replication. Some of the common T>C and C>T transitions in the hypervariable
D-Loop and coding regions are potential methylation sites. The D-loop region heteroplasmic
variant T16519C that we previously reported as associated with SZ is a possible candidate for
methylation for instance. A few studies have investigated mitochondrial neuroepigenetics [39,
40], and mtDNA epigenetic changes have recently been observed in mammalian brains with
age and region specific patterns [41]. Thus, rare and common mitochondria sequence variants
while not sufficient to cause a classical mitochondrial disease, may be associated with a cascade
involving altered energy output in brain depending on the functional variants and loss or gain
of methylation sites in the mtDNA especially in the control region (D-Loop).
We paid particular attention to validation of the observed results and confirmed a subset of
variants by Sanger sequencing, allelic specific PCR, and allelic specific PCR using LNA primers.
We selected 6 heteroplasmic variants with high levels of heteroplasmy for confirmation by
Sanger sequencing, while allele specific methods were needed for levels of heteroplasmy be-
tween 10 and 20%. A recent pyrosequencing study of mtDNA in 40 Hapmap reference samples
reported high levels of heteroplasmy but low confirmation ratios using only Sanger sequencing,
even for high heteroplasmy loci (>40%), raising questions about the efficiency of Sanger to de-
tect heteroplasmy [42]. However, the coverage in that study was lower than ours which might
explain why some of the heteroplasmic variants observed were false positives. Additionally,
misinterpretation of the chromatograms could also explain some of the observed discordant re-
sults, like the G1333A locus that is clearly heteroplasmic but was interpreted as homoplasmic
[42].
Homoplasmic variants
We observed 49 non-synonymous variants at 37 loci that were specific to cases, not found in
controls (Table 1), 8 of these were predicted using Polyphen as being possibly/probably
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damaging mutations and could potentially have a functional role in mitochondrial dysfunction
and psychiatric disorders. In SZ we observed a particularly high number of non-synonymous
mutations per subject (22 variants) (Table 2) when compared to non-synonymous variants
specific to controls (11 variants). When translated into a Z-score there was an excess of non-
synonymous mutations (p = 0.024, two tailed z-score test) in SZ compared to controls. This
suggests a higher burden of non-synonymous mutations in SZ and we are conducting new ex-
periments in a larger sample for robust replication. Most of these 49 known non-synonymous
variants were not previously associated with any known mitochondrial disorder, ruling out the
likelihood that a formal mitochondrial disorder is underlying these psychiatric disorders in this
study. However the rate of rare-novel mutations is 5 in 42 psychiatric cases and 2 in 22 controls
(Table 3), indicating that our sample surpasses the percentages recently reported for mutation
rates in screening mitochondrial genomes from symptomatic patients (3%-6%)[43]. We ex-
cluded the common haplogroup defining non-synonymous mutations from our calculations,
thus we are cautiously optimistic about excess non-synonymous SNPs dispersed across the
mtDNA genome and the trend towards an excess in psychiatric disorders particularly in
schizophrenia. In the present mtDNA data, the lack of haplogroup specificity for these muta-
tions supports prior literature that has mainly failed to consistently demonstrate differences be-
tween major haplogroups in terms of prevalence of psychiatric disorders [4, 5].
Heteroplasmic Variants
We found novel heteroplasmic loci using NGS. Due to higher sequencing depth and hence
higher sensitivity, heteroplasmy as well as somatic mutations are more likely to be detected and
reported with NGS as opposed to Sanger sequencing experiments, SNaPshot, Surveyor, etc.
[19, 22, 44]. Other technologies such as Sanger sequencing or allelic specific PCR using LNA-
primers, must be used to validate heteroplasmy, as we and others find multiple instances of
false positives [19, 45].
In general, heteroplasmy can occur in germ-line and become equally distributed throughout
many tissues, but it has also been suggested to be a consequence to the effects of reactive oxy-
gen species and other oxidative stress mechanisms inducing substitutions that are not repaired
during mtDNA replication [46] or during fission/fusion between mitochondria organelles. On
the other hand, recent evidence suggests that somatic mutagenesis is actually influenced by
germline mutations that get disseminated by clonal expansion in somatic tissues which can ex-
plain also the variable levels of heteroplasmy across the brain and in blood observed in the
present study. The present results show equal heteroplasmy in germ-line and brain at some
loci, but other loci showed an increase in heteroplasmy in brain with no heteroplasmy found in
blood. We report low levels of heteroplasmy in brain tissue not present in blood for three con-
trol subjects, underlining the interest in surveying somatic mtDNA variation in brain to uncov-
er mutations possibly involved in neuropsychiatric disorders. Heteroplasmy levels observed in
brain exclusively were relatively low usually less than 10% (S8 Table), while a perfect concor-
dance of homoplasmic variants between the two tissues was observed.
We confirmed heteroplasmy at T16519C, a locus previously reported as being hypermutable
in multiple haplogroups and that we previously found is associated with SZ [9]. Another locus,
T16086C, also showed highly variable levels of heteroplasmy (6.3 to 32.5%) between the brain
regions from the same control individual (Fig 2), suggesting that some brain regions might
reach detrimental levels of heteroplasmy.
Many diseases can be caused by heteroplasmic mtDNA mutations with clinical manifesta-
tion appearing after a certain threshold of mutant heteroplasmy, a concept called phenotypic
threshold effect [47]. Studies have shown heteroplasmy within families and between tissues
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[48], as well as between cancer and non-cancer tissue from the same individual [22]. Recently,
it was shown that heteroplasmy in brain of mice can result in altered metabolic function, as
well as altered behavior and cognitive performance [49]. In this study we observed variable lev-
els of heteroplasmy levels between tissues (blood-brain) and within tissue between brain re-
gions from the same individual, pointing to somatic or postzygotic mutations within cells in
certain parts of the brain of control subjects. Although no psychiatric cases were assayed for
heteroplasmy across brain regions in the present study, we found within controls that hetero-
plasmic mutations can vary between brain regions from the same individual (Fig 2). Low fre-
quency somatic mutations have also been discovered in patients with neurological disorders by
whole exome NGS [44]. The authors of the study point to low frequency of mutations in blood
as evidence of mosaicism only detectable by high coverage NGS sequencing (>1000X), howev-
er as the authors point out they did not have access to brain tissue to determine the distribution
of somatic variants associated with the observed neurological alterations [44]. Thus, we will se-
quence additional brain samples from subjects with psychiatric disorders, to address hetero-
plasmy across brain regions as a potential indicator of mitochondrial dysfunction.
Multiplasmy
Multiplasmy was observed in three loci located in the D-loop region (D310, D16189 and 514–
523(CA)n). Two of these multiplasmy loci consist of poly cytosine tracts interrupted by a thy-
midine at positions 310 and 16189. These two regions are known to be highly variable and are
potentially associated with mitochondria copy number and neurological disorders [29, 50, 51].
Multiplasmy at these loci has been confirmed by cloning and Sanger sequencing [52, 53]. Mul-
tiplasmy was also observed at the 514–523 (CA)n locus (S2 Fig), a phenomenon previously re-
ported and confirmed by Sanger sequencing [54]. This multiplasmy occurs 1.5 times more
frequently in psychiatric cases compared to controls at 514 CA dinucleotide repeat, albeit in a
small sample this is not significant (p = 0.14). Multiplasmy in this region can perhaps induce
differences in transcription, since this region is at the border of binding of TFAM1 to mtDNA
at bp 523–550. We observed variation in multiplasmy levels versus wild type at this locus across
brain regions (S2 Fig), but multiplasmy was present in all the brain regions examined. The in-
creased multiplasmy in psychiatric brains, while not significant, is perhaps another indicator
suggesting an involvement of genetic instability of mtDNA in the predisposition to
psychiatric disorders.
In conclusion, we observed several new and rare mitochondrial non-synonymous mutations
in psychiatric cases and excess non-synonymous mtDNA mutations in persons with schizo-
phrenia (Table 1). These findings support the hypothesis that common and rare mitochondrial
mutations can play a role in psychiatric disorders, especially schizophrenia [9, 14–16]. Addi-
tionally, in a preliminary analysis, we observed a higher proportion of multiplasmic and het-
eroplasmic burden primarily in the hyper-variable region in psychiatric cases which was not
significantly different from controls. Although speculative, these data point to a higher geno-
mic instability in the mtDNA of psychiatric patients. It is widely known that mtDNA has a
higher mutation rate than nuclear DNA, lacks protective histones, and undergoes genomic rep-
lication independent of cell division, all of which contribute to functional mutations. Our ob-
servations are in agreement with recent reports of an excess of non-synonymous variants in
nuclear genes [55] and a higher rate of de novomutations in nuclear genes in schizophrenia
[56], as well as somatic mutations present in neurological disorders [44, 57, 58]. A larger study
is required in multiple brain regions and blood to directly test our hypothesis that rare and
novel mutations in mtDNA are enriched in psychiatric cases.
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Materials and Methods
Subjects
Anonymized and de-identified post-mortem human brain samples were obtained from the
University of California, Irvine Brain Bank (UCIBB: www.vawterlab.com). This study was ap-
proved by the Institutional Review Board (IRB) of the University of California, Irvine. Signed
informed consent was obtained from next of kin. A total of 14 BD (5F/9M, 54±12yr), 20 con-
trols (5F/15M, 50±18 yr), 15 MDD (8F/7M, 45±12 yr), 14 SZ (7F/7M, 44±9), as well as 6 meth-
amphetamine users with no axis I diagnosis (METH; 4F/2M, 42±8 yr), were analyzed (S1 and
S2 Tables) resulting in 121 complete mtDNA sequences from 69 subjects. We presented
homoplasmic NGS data for 23 of the subjects (cohort 1) in a recent paper [9], in this study we
explored also heteroplasmic and multiplasmic mutations in 46 new subjects (cohort 2). In sum-
mary, all 69 subjects had the DLPFC sequenced and for a subset of subjects blood as well as
other brain regions depending on availability of tissue were also sequenced.
Eleven brain regions were dissected on dry ice from the left hemisphere according to visible
landmarks near the regions of interest. DNA was extracted from the following brain regions:
anterior cingulate cortex (ACC), amygdala (AMY), caudate nucleus (CAUN), cerebellum
(CB), dorsolateral prefrontal cortex (DLPFC), hippocampus (HIPP), nucleus accumbens
(NACC), orbitofrontal cortex (OFC), putamen (PUT), substantia nigra (SN), and thalamus
(THAL) for 11 subjects and whole blood was also obtained for three of those subjects. DNA
was extracted from 25 mg of dissected brain tissue using the DNeasy Blood and Tissue Kit
(QIAGEN), according to the manufacturer’s protocol. Previously, DNA was extracted from
DLPFC samples (cohort 1) using the phenol phase of a Trizol protocol and precipitated with
ethanol [59]. Additional details are available in S1 Methods.
Next-Generation Sequencing Analysis
Mitochondrial NGS was performed as described previously [9]. Briefly, two overlapping
mtDNA fragments were PCR amplified, purified, and sequenced using standard manufactur-
er’s protocols. Reads from Illumina GAII (cohort 1) and HiSeq (cohort 2) were aligned to the
mitochondrial revised Cambridge Reference Sequence (rCRS; GenBank accession number
NC_012920)[27]. We defined homoplasmic mutations as genetic variants for which the major
allele was different from the rCRS and constituted 95% to 100% of the reads. Heteroplasmic
mutations were therefore defined as any variant for which the major allele was<95% of the
total of the observed alleles. For both homoplasmy and heteroplasmy we filtered out variants
with coverage lower than 200 reads. These cutoffs were implemented based on our experience
with false positive mutations in problematic regions of the mtDNA. All the mutations reported
were successfully confirmed by Sanger sequencing. We focused on results from the DLPFC
Table 5. Sequencing error hotspots in mtDNA.
Position Context Variant N (samples)#
302 accaaAccccc A/C 47
3492 ctaaaAcccgc A/C 106
6419 ataaaAccccc A/C 109
10306 aactaAcctgc A/C 41
Four variant loci not previously reported showed heteroplasmic A/C transversions in a large number of samples that could not be validated by Sanger
sequencing or by allele speciﬁc PCR using LNA-primers.
# 121 samples were sequenced (S2 Table), this column shows the number of samples with the aberrant mutations that were errors.
doi:10.1371/journal.pone.0127280.t005
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and SN for reasons of clarity and space (n = 69 unique subjects). We determined whether the
mutations were novel or rare by investigating their presence in curated online databases such
as MITOMAP containing more than 26,850 Genbank mtDNA sequences [60], mtDB [61], and
PhyloTree [28], and also by searching individual genealogical studies reporting mtDNAmuta-
tions using Google as suggested [62]. We also compared our sequence variant results to refer-
ence databases, 1000 Genomes mitochondrial variants, and to the Phylotree database that
contains over 16,500 mtDNA genomes which overlaps MITOMAP. The effect of amino acid
substitutions was determined using Polyphen [63, 64].
Quality control was critical especially for heteroplasmic variants. Heteroplasmic A>C vari-
ants were observed in many brain samples in the same loci of the mtDNA genome. However,
we were unable to confirm these variants using Sanger sequencing or allele specific PCR with
locked nucleic acids (Table 5). Some of these error hotspots have been previously reported
using the Illumina platform [19]. We noted a disproportionate number of A>C heteroplasmic
substitutions (148 out of 401 heteroplasmic variants) which was more than what would be ex-
pected, as transversions occur less frequently than transitions. Two previously reported error
hotspots in Illumina NGS [19], the A3492C and A10306C loci, and a transversion never re-
ported at position A6419C were frequently observed (Table 5). Three other non A/C hetero-
plasmic positions that did not validate were T3488A, T6415A, and G9801T. Closer
examination of the sequence surrounding the A>C sequencing error hotspots revealed a com-
mon motif of at least two A nucleotides followed by at least two C nucleotides (Table 5). We
choose for validation 6 of the heteroplasmic variants with heteroplasmy levels of more than
10% to be confirmed by Sanger sequencing and they were all successfully confirmed.
Supporting Information
S1 Fig. Phylogenetic tree of mtDNA variants observed in the present cohort. The first letter
of the subject label corresponds to the diagnosis (B: bipolar disorder; S: schizophrenia; M:
major depression; D: drugs (methamphetamine)), the number is the age of the subject, and the
letter after the age is the gender (F: female; M: male).
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S2 Fig. The ratio of the deletion to wild type at 514 CA across brain regions. Note for both




S1 Table. Subject demographics by NGS platform.
(DOCX)
S2 Table. Number of samples processed in brain and blood for next generation sequencing.
(DOCX)
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S5 Table. The distribution of subjects by number of non-synonymous coding mutations
categorized by diagnosis. There was a non-significant excess of 5+ mutations in cases com-
pared with controls (Fishers Exact Test, one-sided p = 0.068).
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